Overview

Generic Drugs (Dapagliflozin and Saxagliptin) Treat Type 2 Diabetes Patients With Controlled Cancers

Status:
ACTIVE_NOT_RECRUITING
Trial end date:
2026-11-28
Target enrollment:
Participant gender:
Summary
Use Dapagliflozin 10 mg, Saxagliptin 5 mg, Metformin 500 mg treat type 2 diabetes patients with controlled cancers
Phase:
PHASE2
Details
Lead Sponsor:
Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair
Collaborator:
UnitedHealthcare
Treatments:
dapagliflozin
saxagliptin